Moonlake Immunotherapeutics (MLTX) Stock Price, Quote & News

Company Profile

MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerla...

Industry: Biotechnology

Sector: Healthcare

Phone: 41 415108022

Website: www.moonlaketx.com

Address:

Dorfstrasse 29, Zug, Switzerland

WallStWolf38 Sep. 13 at 2:42 PM

$MLTX MLTX got hit hard this week, but IMO the fundamentals haven’t materially changed. The selloff looks more like a broader clinical biotech risk-off move, driven by high interest rates + recent failed trials (like. Novartis), rather than MoonLake-specific bad news. Sonelokimab data remain intact, HS Best in class, PsA data were positive, 500M+ cash, and the BLA filing is approaching. A successful filing should remove a major part of the current uncertainty. I wouldn’t be surprised by a 30–50% + rebound on a strong BLA/PR. We’ve seen this before: in January MLTX was pushed from usd 15 to usd 11, only to jump 60% in two days after positive PR.

1 · Reply

TradingVolume Sep. 13 at 1:16 PM

$MLTX < !

1 · Reply

aletz Sep. 13 at 12:13 PM

$MLTX I agree with Cresi that trying to go solo on commercialization is just sheer madness.

1 · Reply

AXMO Sep. 13 at 8:11 AM

$MLTX

0 · Reply

RolexKingUSA Sep. 12 at 10:34 PM

$MLTX if this goes back up to all time highs ill be happy.

0 · Reply

Darth_Barrister Sep. 12 at 1:21 PM

$MLTX The price action is, of course, frustrating. However, maybe this will humble management a little and get them to take partnership or BO possibilities more seriously (?).

1 · Reply

benthebenben Sep. 12 at 12:54 PM

$MLTX FDA already aligned with MoonLake on the data package twice — the January 2026 Type B meeting outcome (confirmed the VELA-1 + VELA-2 + MIRA package can establish "substantial evidence of effectiveness" without further trials) and the May 2026 final pre-BLA meeting (reaffirmed it). What's due end of November isn't an approval/CRL decision — it's the 60-day filing review, where the FDA decides "filed" vs. "refuse to file" (RTF), a check for administrative/technical completeness, not efficacy. RTF exists specifically to catch submissions the agency wasn't consulted on. Since the strategy here was pre-agreed with the FDA nearly a year in advance, predicting an RTF isn't "a common pattern for small companies" — it's an unsupported guess with no cited precedent or specific deficiency. Worth noting as a real risk, but "likely" overstates it based on what's publicly known.

2 · Reply

Antocar Sep. 12 at 11:54 AM

$MLTX This is just my opinion, but I think the BLA submission will have some problems during the first submission. This often happens to small companies like MLTX. It will probably be accepted in a second round, which is why I'm prepared for an imminent 50-60% drop and buy shares at $5-6. Obviously, this is just my personal opinion. Everyone has to think for themselves.

0 · Reply

Antocar Sep. 12 at 11:41 AM

$MLTX IZAR has disappointed investors and cast doubt on the theory that nanobodies are superior to standard antibodies. If IZAR disappoints in 2027, it will be a failure, and MLTX will collapse miserably, so we'll have to wait for IZAR at 52 weeks.

0 · Reply

benthebenben Sep. 12 at 8:46 AM

$MLTX https://tickeron.com/blogs/moonlake-immunotherapeutics-mltx-is-a-rebound-to-30-in-sight-16391/

1 · Reply

MoonLake price target raised to $50 from $45 at H.C. Wainwright

Aug 10, 2026, 8:07 AM EDT - 4 weeks ago

MoonLake's psoriatic arthritis drug meets key goals in late-stage trial

2026-08-10T11:45:28.000Z - 4 weeks ago

MoonLake Immunotherapeutics reports Q2 EPS (84c), consensus (90c)

2026-08-10T11:40:14.000Z - 4 weeks ago

MoonLake says Phase 3 IZAR-1 trial met all clinical endpoints at Week 16

Aug 10, 2026, 7:00 AM EDT - 4 weeks ago

MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial Results

Aug 10, 2026, 7:00 AM EDT - 4 weeks ago

MoonLake Immunotherapeutics Earnings release: Q2 2026

Aug 10, 2026, 7:00 AM EDT - 4 weeks ago

MoonLake Immunotherapeutics Quarterly report: Q2 2026

2026-06-24T10:25:15.000Z - 2 months ago

MoonLake Immunotherapeutics 9M share Secondary priced at $20.00

Jun 23, 2026, 11:08 PM EDT - 2 months ago

MoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public Offering

2026-06-22T20:17:49.000Z - 2 months ago

MoonLake Immunotherapeutics announces $150M offering of Class A ordinary shares

Jun 22, 2026, 4:01 PM EDT - 2 months ago

MoonLake Immunotherapeutics Announces Proposed Public Offering

2026-06-22T17:45:23.000Z - 2 months ago

MoonLake’s SLK has ‘blockbuster potential,’ says Clear Street

Jun 22, 2026, 8:00 AM EDT - 2 months ago

MoonLake Immunotherapeutics Transcript: Investor Day 2026

Jun 22, 2026, 8:00 AM EDT - 2 months ago

MoonLake Immunotherapeutics Slides: FY 2026

2026-06-22T01:20:59.000Z - 2 months ago

MoonLake announces Week 52 results of Phase 3 VELA-1, VELA-2 trials

Jun 21, 2026, 5:00 PM EDT - 2 months ago

MoonLake Announces Week 52 Results of Sonelokimab from its Phase 3 VELA Program in Hidradenitis Suppurativa and Confirms Investor Day on June 22, 2026

May 11, 2026, 7:00 AM EDT - 4 months ago

MoonLake Immunotherapeutics Earnings release: Q1 2026

May 11, 2026, 7:00 AM EDT - 4 months ago

MoonLake Immunotherapeutics Quarterly report: Q1 2026

2026-05-11T10:50:53.000Z - 4 months ago

MoonLake price target raised to $45 from $40 at H.C. Wainwright

2026-05-10T19:10:05.000Z - 4 months ago

MoonLake FDA meeting yields ‘best-in-class’ label, says Clear Street

2026-05-10T18:50:45.000Z - 4 months ago

MoonLake says aligned with FDA on submission plans for sonelokimab

2026-05-10T18:50:05.000Z - 4 months ago

MoonLake Immunotherapeutics reports Q1 EPS -98c vs. -91c last year

May 10, 2026, 9:00 AM EDT - 4 months ago

MoonLake Immunotherapeutics Announces Positive Outcome from its Final Pre-BLA Meeting with the U.S. FDA and Reports First Quarter 2026 Financial Results

Apr 21, 2026, 8:00 AM EDT - 4 months ago

MoonLake Immunotherapeutics Proxy statement: Proxy filing

Apr 21, 2026, 8:00 AM EDT - 4 months ago

MoonLake Immunotherapeutics Proxy statement: Proxy filing

2026-03-29T14:35:05.000Z - 5 months ago

MoonLake Immunotherapeutics announces results from Phase 3 VELA-1, VELA-2 trial

Mar 28, 2026, 3:00 PM EDT - 5 months ago

MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting

2026-03-26T17:25:33.000Z - 5 months ago

MoonLake Immunotherapeutics management to meet with BTIG

2026-03-23T09:45:29.000Z - 5 months ago

MoonLake upgraded to Outperform from Underperform at Wolfe Research

2026-03-19T08:50:28.000Z - 5 months ago

MoonLake upgraded to Buy from Neutral at Rothschild & Co Redburn

2026-03-11T10:36:37.000Z - 6 months ago

MoonLake price target raised to $70 from $45 at Clear Street

Feb 23, 2026, 8:00 AM EST - 6 months ago

MoonLake Immunotherapeutics Transcript: Investor Day 2026

Feb 23, 2026, 8:00 AM EST - 6 months ago

MoonLake Immunotherapeutics Slides: FY 2026

Feb 22, 2026, 4:00 PM EST - 6 months ago

MoonLake Immunotherapeutics Annual report: Q4 2025

Feb 22, 2026, 4:00 PM EST - 6 months ago

MoonLake Immunotherapeutics Earnings release: Q4 2025

Feb 10, 2026, 7:00 AM EST - 7 months ago

ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer

IMA

Feb 2, 2026, 8:00 AM EST - 7 months ago

MoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor Day

Jan 27, 2026, 7:30 AM EST - 7 months ago

Helix Acquisition Corp. III Announces Closing of $172.5 Million Initial Public Offering, Including the Full Exercise of the Underwriter's Option to Purchase Additional Shares

Jan 23, 2026, 7:30 AM EST - 7 months ago

Helix Acquisition Corp. III Announces Pricing of Upsized $150 Million Initial Public Offering

Dec 11, 2025, 8:54 AM EST - 9 months ago

DEADLINE NEXT WEEK: Berger Montague Advises MoonLake Immunotherapeutics (NASDAQ: MLTX) Investors to Contact the Firm Before December 15, 2025

Dec 5, 2025, 8:18 AM EST - 9 months ago

MoonLake Immunotherapeutics (MLTX) Investors are Encouraged to Act before the Upcoming December 15 Securities Fraud Deadline – Contact BFA Law if You Lost Money

Dec 3, 2025, 7:46 AM EST - 9 months ago

MLTX NEWS: MoonLake Immunotherapeutics Sued for Securities Fraud after Stock Plummets 90% -- Investors Notified to Contact BFA Law by December 15 Deadline

Dec 1, 2025, 3:18 PM EST - 9 months ago

MLTX SHAREHOLDERS: MoonLake Immunotherapeutics Investors with Losses may have been Misled by the Company and are Urged to Contact BFA Law by December 15

Nov 30, 2025, 7:45 AM EST - 9 months ago

MLTX LAWSUIT: BFA Law Reminds MoonLake Immunotherapeutics Investors the Company has been Sued for Securities Fraud and to Contact BFA Law by December 15 Deadline

Nov 24, 2025, 6:08 AM EST - 9 months ago

MOONLAKE NOTICE: MoonLake Immunotherapeutics (MLTX) Faces Securities Fraud Allegations after Stock Drops 90%, Investors Urged to Contact BFA Law

Nov 14, 2025, 6:08 AM EST - 10 months ago

MOONLAKE INVESTORS: MoonLake Immunotherapeutics (MLTX) has been Sued for Securities Fraud, Investors are Urged to Contact BFA Law

Nov 10, 2025, 8:15 AM EST - 10 months ago

MOONLAKE IMMUNOTHERAPEUTICS (NASDAQ: MLTX) DEADLINE ALERT Bernstein Liebhard LLP Reminds MoonLake Immunotherapeutics Investors of Upcoming Deadline

Nov 10, 2025, 6:06 AM EST - 10 months ago

MLTX STOCK NOTICE: MoonLake Immunotherapeutics Investors with Losses may have been Misled by the Company and are Urged to Contact BFA Law by December 15 Deadline

Nov 5, 2025, 4:00 PM EST - 10 months ago

MoonLake Immunotherapeutics Earnings release: Q3 2025

Nov 5, 2025, 4:00 PM EST - 10 months ago

MoonLake Immunotherapeutics Quarterly report: Q3 2025

Nov 5, 2025, 7:11 AM EST - 10 months ago

MoonLake Immunotherapeutics Announces Pricing of $75 Million Underwritten Offering

Nov 5, 2025, 7:00 AM EST - 10 months ago

MoonLake Immunotherapeutics Reports Third Quarter 2025 Financial Results and Announces New Data from Clinical Trials of its Nanobody® Sonelokimab

Nov 1, 2025, 7:08 AM EDT - 10 months ago

MLTX INVESTOR REMINDER: MoonLake Immunotherapeutics Investors may have been Affected by Fraud -- Contact BFA Law if You Suffered Losses

WallStWolf38 Sep. 13 at 2:42 PM

1 · Reply

TradingVolume Sep. 13 at 1:16 PM

$MLTX < !

1 · Reply

aletz Sep. 13 at 12:13 PM

$MLTX I agree with Cresi that trying to go solo on commercialization is just sheer madness.

1 · Reply

AXMO Sep. 13 at 8:11 AM

$MLTX

0 · Reply

RolexKingUSA Sep. 12 at 10:34 PM

$MLTX if this goes back up to all time highs ill be happy.

0 · Reply

Darth_Barrister Sep. 12 at 1:21 PM

$MLTX The price action is, of course, frustrating. However, maybe this will humble management a little and get them to take partnership or BO possibilities more seriously (?).

1 · Reply

benthebenben Sep. 12 at 12:54 PM

2 · Reply

Antocar Sep. 12 at 11:54 AM

0 · Reply

Antocar Sep. 12 at 11:41 AM

0 · Reply

benthebenben Sep. 12 at 8:46 AM

$MLTX https://tickeron.com/blogs/moonlake-immunotherapeutics-mltx-is-a-rebound-to-30-in-sight-16391/

1 · Reply

Jkm11 Sep. 12 at 7:38 AM

$MLTX what a crazy ride this last month. Never would have guessed the major slide in price. I have a good cache of shares and still believe in the SLK outcome, but this is one of those times when one's patience and convictions are truly tested. We all know this company is worth more than 20 bucks. This is an awesome time for those who exited to get back in and for those of us holding to perhaps increase our positions. I thought my buying of moonlake was pretty much over, but if prices are going to stay this low id be crazy to not get a bit more. Cant wait to see how the next 6 to 9 months shake out. Thanks to everyone providing updates of moonlake happenings during the day. We shall have our day sometime soon.

0 · Reply

Obidagreat Sep. 12 at 6:11 AM

$MLTX

0 · Reply

benthebenben Sep. 12 at 6:01 AM

$MLTX

0 · Reply

benthebenben Sep. 12 at 5:59 AM

$MLTX https://seekingalpha.com/article/4943841-moonlake-immunotherapeutics-the-bull-case-does-not-require-clinical-supremacy

0 · Reply

insomniaot7 Sep. 12 at 3:41 AM

$MLTX at this rate... I'll buy back in when it hits my original entry from last fall 😂

1 · Reply

Antocar Sep. 11 at 11:50 PM

$MLTX the IZAR data seem to be disappointing. So SLK doesn't work? No, SLK works, but like many other drugs, or even less. So the company's value is greatly diminished, and the nanoboby theory is a failure. If IZAR is inferior to other therapies at 52 weeks, MLTX will go below $5. SLK was expected to be much more effective than its competitors, but perhaps that's not the case.

2 · Reply

et1000 Sep. 11 at 11:17 PM

Ticker MLEC is the next nano float runner ! Every small float ticker has been running almost 500% recently Would not be surprised if they send MLEC up next. MLEC starting to make its move now! Only 573k shares outstanding! 💎 $BBBYW $MLTX $BBY SDJ

0 · Reply

LouKojak Sep. 11 at 10:26 PM

$MLTX bought

0 · Reply

LouKojak Sep. 11 at 10:08 PM

$MLTX strongly considering buying on monday

0 · Reply

Wild_West23 Sep. 11 at 9:31 PM

$MLTX I agree brother. However just a year ago it was sitting at $7 following a massive drop from $60. Hard to say where this goes short term, but I like the long play here for sure.

0 · Reply

Dino132613 Sep. 11 at 9:30 PM

$MLTX very simple market-cap-plus-debt-minus-cash basis, the market is valuing the operating business/sonelokimab platform at only about $620M. That calculation is simplified and does not capture every balance-sheet or fully diluted item, but it illustrates how aggressively the market is discounting regulatory and commercial risk. Retail is along for ride. Shorts are winning price battle!

0 · Reply

Antocar Sep. 11 at 9:21 PM

$MLTX under $10 soon

0 · Reply

Market Cap	1.06B
Revenue (ttm)	0.00
Net Income (ttm)	-227.32M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.23

Volume	2,387,100
Avg Vol	1,234,528
Day's Range	N/A - N/A
Shares Out	85.11M
Stochastic %K	1%
Beta	1.04
Analysts	Strong Sell
Price Target	$33.46